A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation

Project: Other project

Project Details

StatusFinished
Effective start/end date11/7/1911/6/22

Funding

  • Sanofi US Services Inc: $38,287.43